TITLE

Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial

AUTHOR(S)
Parikh, Anish; Kozuch, Peter; Rohs, Nicholas; Becker, Daniel; Levy, Benjamin
PUB. DATE
December 2017
SOURCE
Investigational New Drugs;Dec2017, Vol. 35 Issue 6, p813
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background Metformin has been shown to have anti-neoplastic activity in non-small cell lung cancer (NSCLC) in both preclinical and observational studies, however this has never been prospectively evaluated. This single-arm phase II trial, while not fully accrued, is the first known prospective study evaluating the use of metformin with chemotherapy in advanced NSCLC. Methods Patients received carboplatin AUC 5 + pemetrexed 500 mg/m2 IV every 21 days for 4 cycles. For patients who achieved at least stable disease, maintenance pemetrexed was administered until progression or toxicity. Metformin was initiated at 1000 mg/day for week 1, 1500 mg/day for week 2, then 2000 mg/day thereafter, in divided doses. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), duration of response (DOR), and adverse events (AE). Tumor tissue was tested for LKB1/STK11 mutations, and non-fasting serum insulin levels were longitudinally assessed. Results Of a planned 50 patients, 14 were enrolled. ORR was 23% and median PFS was 3.9 months. Median OS was 11.7 months. No LKB1/STK11 mutations were identified. The most common AE were fatigue (42.9%), anemia, and nausea (28.6% each). The most common grade III AE was nausea (14.3%). No grade IV AE occurred. Mean duration of metformin treatment was 5.6 months. Conclusion Adding metformin to chemotherapy for advanced NSCLC was safe but did not significantly improve clinical outcomes compared to historical phase III controls. These results are limited by the small sample size; larger trials are needed.
ACCESSION #
126307955

 

Related Articles

  • nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer. LAMMERS, PHILIP EDWARD; BO LU; HORN, LEORA; YU SHYR; KEEDY, VICKI // Oncologist;May2015, Vol. 20 Issue 5, p491 

    Background. Unresectable stage III non-small cell lung cancer (NSCLC) has a 5-year survival rate of 20%, and concurrent chemoradiotherapy results in significant toxicity with the use of current chemotherapeutic agents. nab-Paclitaxel was approved by the U.S. Food and Drug Administration in...

  • Local Treatment Combined with EGFR-TKIs for Advanced Non-small Cell Lung Cancer with Solitary Progression during EGFR-TKI Treatment. Xin ZHANG; Bin WANG; Lin LIN; Xuezhi HAO; Shanshan CHEN; Junling LI; Xiangru ZHANG; Yuankai SHI // Chinese Journal of Lung Cancer;Oct2013, Vol. 16 Issue 10, p514 

    Background and objective Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are routine treatments for non-small cell lung cancer (NSCLC) with EGFR mutation. Different clinical modes can be used to treat patients with TKI resistance, one of which is solitary progression. The...

  • A Phase II Study of Amrubicin as a Third-Line or Fourth-Line Chemotherapy for Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901. Toshiyuki Harada; Satoshi Oizumi; Kenichiro Ito; Kei Takamura; Eiki Kikuchi; Tomoya Kuda; Shunichi Sugawara; Aya Suzuki; Makoto Maemondo; Yuka Fujita; Ichiro Kinoshita; Akira Inoue; Fumihiro Hommura; Yutaka Katsuura; Hirotoshi Dosaka-Akita; Hiroshi Isobe; Kmasaharu Nishimura // Oncologist;Apr2013, Vol. 18 Issue 4, p439 

    Amrubicin, a third-generation synthetic anthracycline agent, has favorable clinical activity and acceptable toxicity for the treatment of patients with non-small cell lung cancer (NSCLC) and small cell lung cancer. We conducted this study to evaluate the efficacy and safety of amrubicin for...

  • Preoperative Cetuximab, Irinotecan, Cisplatin, and Radiation Therapy for Patients With Locally Advanced Esophageal Cancer. Lee, Michael S.; Mamon, Harvey J.; Hong, Theodore S.; Choi, Noah C.; Fidias, Panagiotis M.; Kwak, Eunice L.; Meyerhardt, Jeffrey A.; Ryan, David P.; Bueno, Raphael; Donahue, Dean M.; Jaklitsch, Michael T.; Lanuti, Michael; Rattner, David W.; Fuchs, Charles S.; Enzinger, Peter C. // Oncologist;Mar2013, Vol. 18 Issue 3, p281 

    Purpose.To determine the efficacy and toxicity of weekly neoadjuvant cetuximab combined with irinotecan, cisplatin, and radiation therapy in patients with locally advanced esophageal or gastroesophageal junction cancer. Methods and Materials. Patients with stage IIA-IVA esophageal or...

  • Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. Russo, Francesca; Bearz, Alessandra; Pampaloni, Gianni // BMC Cancer;2008, Vol. 8, Special section p1 

    Background: The main objective of this study was to evaluate the safety of second-line pemetrexed in Stage IIIB or IV NSCLC. Methods: Overall, 95 patients received pemetrexed 500 mg/m² i.v. over Day 1 of a 21-day cycle. Patients also received oral dexamethasone, oral folic acid and i.m....

  • A Randomized Clinical Study of Gefitinib and Pemetrexed as Second Line Therapy for Advanced Non-squamous Non-small Cell Lung Cancer. Hongyu DAI; Ling XU; Chunwei XIA; Wenping CHEN // Chinese Journal of Lung Cancer;Aug2013, Vol. 16 Issue 8, p405 

    Background and objective Gefitinib and Pemetrexed are drugs used as second-line therapy for advanced non-small cell lung cancer (NSCLC), although studies comparing the two drugs are limited. The aim of this study is to explore the effects, safety, and quality of life (QoL) of Gefitinib and...

  • Amgen, Takeda's Lung Cancer Drug Stumbles in Phase III. Shaffer, Catherine // BioWorld Today;3/31/2011, Vol. 22 Issue 62, p2 

    This article reports on the release of top-line results of a Phase III trial of a VEGF inhibitor, motesanib, for nonsquamous non-small-cell lung cancer (NSCLC) by Amgen Inc. and Takeda Pharmaceutical Co. Ltd. in 2011. Both companies expressed disappointment regarding the results. The trial...

  • NONSMALL-CELL LUNG CANCER: MAINTENANCE THERAPY. Kim, Edward // Johns Hopkins Advanced Studies in Medicine;Nov2011, Vol. 11 Issue 2, p33 

    The article focuses on the maintenance therapy of nonsmall-cell lung cancer (NSCLC). It mentions that maintenance therapy is applied in patients whose tumors have reacted to first-line chemotherapy. It says that the maintenance therapy aims to prolong their progression-free survival (PFS) and...

  • FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements. Kazandjian, Dickran; Blumenthal, Gideon M.; Huan-Yu Chen; Kun He; Patel, Mona; Justice, Robert; Keegan, Patricia; Pazdur, Richard // Oncologist;Oct2014, Vol. 19 Issue 10, preceding, following pe5 

    On August 26, 2011, crizotinib received accelerated approval for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by a test approved by the U.S. Food and Drug Administration (FDA). Approval was based on two...

  • Clinical Observation of EGFR-TKI as A First-line Therapy on Advanced Non-small Cell Lung Cancer. Jianjie Li; Lili Qu; Xing Wei; Hongjun Gao; Weixia Wang; Haifeng Qin; Chuanhao Tang; Wanfeng Guo; Hong Wang; Xiaoqing Liu // Chinese Journal of Lung Cancer;May2012, Vol. 15 Issue 5, p299 

    Abstract Background and objective It has been proven that epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) significantly benefits advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations in progression-free survival time with better tolerance. This study...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics